Mar 13, 2018
The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes.
Precision medicine allows detailed insights into the disease processes that underlie clinical disease. This field has first started with genetics, and genetic mutation-based models that can predict disease state such as tumour phenotype or likely therapeutic response are gaining much ground in oncology.
The original article this episode is based on was written by Billy Boyle and Dr Mike Murphy. If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: